In Brief: SmithKline Beecham's Relafen
Executive Summary
SmithKline Beecham's Relafen: Chewable 1 gm tablet form of the NSAID nabumetone gains "approvable" status Feb. 16. The higher strength tablet will allow for once- or twice-daily dosing for treating osteoarthritis and rhematoid arthritis...